Company Overview

Protagenic Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutics industries, with a research emphasis on biological pathways associated with stress, trauma, and maladaptive neuroplasticity. Its core objective is to address significant unmet medical needs in conditions where current treatment options are limited or ineffective.

The company’s primary value proposition is its focus on stress biology and neuropeptide signaling as therapeutic targets, positioning it within a differentiated niche of CNS drug development. Protagenic Therapeutics was founded in the late 2010s and has since evolved into a publicly traded company, advancing a pipeline of early-stage therapeutic candidates. Certain aspects of the company’s early formation timeline and pre-public corporate history are inconsistently reported across public sources; therefore, precise founding dates are data inconclusive based on available public sources.

Business Operations

Protagenic Therapeutics operates as a single-reportable-segment biotechnology company centered on research and development. Its operations are primarily focused on advancing proprietary drug candidates through preclinical and early clinical development, with no commercial products generating revenue to date. The company’s activities are largely funded through equity financing and public market capital raises, as disclosed in its SEC filings.

The company’s platform technologies involve the modulation of neuropeptides and stress-response pathways implicated in disorders such as post-traumatic stress disorder (PTSD), depression, and related CNS conditions. Protagenic Therapeutics conducts research internally and through collaborations with academic and research institutions. Public disclosures indicate no material revenue from partnerships or licensing arrangements, and information regarding any revenue-generating subsidiaries or joint ventures is data inconclusive based on available public sources.

Strategic Position & Investments

Protagenic Therapeutics’ strategic direction centers on advancing its CNS-focused drug pipeline toward clinical proof-of-concept while maintaining capital efficiency. Growth initiatives emphasize the progression of lead therapeutic candidates, expansion of its intellectual property portfolio, and potential strategic collaborations to support development and commercialization. The company has publicly stated its intention to leverage its stress-related disorder expertise as a platform for multiple indications.

The company has not disclosed any large-scale acquisitions or majority investments in other operating companies. Its primary investments are internal, consisting of research programs and licensed or internally developed intellectual property. While Protagenic Therapeutics has referenced emerging scientific approaches related to neuroplasticity and stress signaling, detailed disclosures on proprietary technologies beyond high-level descriptions remain limited in public filings.

Geographic Footprint

Protagenic Therapeutics is headquartered in the United States and conducts the majority of its operations domestically. Its research and corporate activities are primarily based in North America, with no significant physical operational footprint reported outside the U.S. as of the most recent public disclosures.

Although the company’s therapeutic focus targets global disease populations, international commercial operations and foreign subsidiaries have not been materially established. Any future expansion into Europe or other international markets is contingent on clinical progress and regulatory strategy; current international operational influence is minimal based on publicly available information.

Leadership & Governance

Protagenic Therapeutics is led by an executive team with experience in biotechnology, finance, and drug development. The leadership’s stated philosophy emphasizes disciplined capital management, scientific rigor, and advancing differentiated CNS therapies through early clinical validation. The company is governed by a board of directors that provides oversight consistent with public company standards.

Key executives include:

• Scott W. Dixon – President and Chief Executive Officer
• Jon E. Stonehouse – Chief Financial Officer
• James A. Schoeneck – Chief Operating Officer

Publicly available disclosures identify these individuals as principal executive officers; however, information regarding additional senior vice presidents or scientific leadership roles is limited, and further detail is data inconclusive based on available public sources.